Citations

Showing 10 of 108081 citations.

SVM Communications: International perspectives on vascular medicine and updates from the Intersocietal Accreditation Commission (IAC)
Brunton, Nichole , Verhaeghe, Raymond, Brunton, Nichole E , Tabares, Aldo Hugo

Mayo Clinic

Vascular Medicine | April 7, 2023 | Volume: 28 | Issue: 2 | Pages: 172-174

10.1177/1358863x231160842 | PMID 37025022 Get It

Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease
Arkhipov, Sergey N. , Potter, D’Anna L., Sultanova, Regina F., Ilatovskaya, Daria V. , Harris, Peter C. , Pavlov, Tengis S. , Harris, Peter C

Mayo Clinic

Physiological Reports | April 6, 2023 | Volume: 11 | Issue: 7 | Pages: No page available

10.14814/phy2.15652 | PMID 37024297 Get It

Abstract Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities. Cystic fluid contains a high level of ATP that, among other effects, leads to a reduced reabsorption of electrolytes in cyst‐lining cells, and thus results in cystic fluid accumulation. Earlier, we demonstrated that Pkd1 RC/RC mice, a hypomorphic model of ADPKD, exhibit increased expression of pannexin‐1, a membrane channel capable of ATP release. In the current study, we found that human ADPKD cystic epithelia have higher pannexin‐1 abundance than normal collecting ducts. We hypothesized that inhibition of pannexin‐1 function with probenecid can be used to attenuate ADPKD development. Renal function in male and female Pkd1 RC/RC and control mice was monitored between 9 and 20 months of age. To test the therapeutic effects of probenecid (a uricosuric agent and a pannexin‐1 blocker), osmotic minipumps were implanted in male and female Pkd1 RC/RC mice, and probenecid or vehicle was administered for 42 days until 1 year of age. Probenecid treatment improved glomerular filtration rates and slowed renal cyst formation in male mice (as shown in histopathology). The mechanistic effects of probenecid on sodium reabsorption and fluid transport were tested on polarized mpkCCD cl4 cells subjected to short‐circuit current measurements, and in 3D cysts grown in Matrigel. In the mpkCCD cl4 epithelial cell line, probenecid elicited higher ENaC currents and attenuated in vitro cyst formation, indicating lower sodium and less fluid retention in the cysts. Our studies open new avenues of research into targeting pannexin‐1 in ADPKD pathology.
A pandemic preparedness network for individuals living with compromised immune systems
Kumar, Shaji , Semmel, Emily A., Hewitt, Kathleen, Plovnick, Robert M., Pappas, Gregory , Kumar, Shaji K , Wood, William A. , Anderson, Kenneth C.

Mayo Clinic

Blood Advances | April 6, 2023 | Volume: 7 | Issue: 15 | Pages: 3925-3927

10.1182/bloodadvances.2023010035 | PMID 37023227 Get It

Blurred Vision After a Kidney Transplant
Tailor, Prashant D. , Smith, Wendy M. , Tailor, Prashant D , Dalvin, Lauren A.

Mayo Clinic

JAMA Ophthalmology | April 6, 2023 | Volume: 141 | Issue: 5 | Pages: 494

10.1001/jamaophthalmol.2023.0707 | PMID 37022701 Get It

A patient with cytomegalovirus viremia who underwent kidney transplant developed floaters in both eyes that did not improve after painful intravitreal injections of foscarnet and ganciclovir. What would you do next?
Beyond the surgical margin: Patterns of recurrence in WHO grade II intracranial meningiomas
Obiri‐Yeboah, Derrick, Oyem, Precious C. , Murayi, Roger , Kshettry, Varun R. , Soni, Pranay , Almeida, João Paulo , Recinos, Pablo F.

Mayo Clinic

No container title available | April 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2778861/v1 Get It

Abstract Purpose To characterize and classify the location of recurrence in surgically resected World Health Organization (WHO) grade II intracranial meningiomas that did not receive adjuvant radiation, and compare the recurrence pattern of those that underwent gross total (GTR) versus subtotal resection (STR). Methods A retrospective review of patients who underwent surgical resection of WHO grade II meningiomas at our institution between 2006 and 2019 was performed. Patients that were observed postoperatively without adjuvant radiation and subsequently developed a recurrence were included. Recurrence was defined as evidence of radiographic progression on postoperative surveillance MRI. Location of recurrence were categorized as: (1)central - growth observed inside the area of the previously resected tumor more than 1 cm inside the original tumor margin; (2)marginal - growth observed within 1 cm (inside or outside) of the original tumor margin; and (3)distant - growth observed more than 1 cm outside of the original tumor margin. Results A total of 22 patients matched the inclusion criteria. Twelve (55%) underwent GTR while ten (45%) underwent STR. Of the GTR patients, ten (83.3%) had central recurrence, 11 (91.7%) had marginal recurrence, and only 4 (33.3%) had distant recurrence. Of the STR patients, 9 (90.0%) had central recurrence, all 10 (100.0%) had marginal recurrence, and only 4 (40.0%) had distant recurrence. Conclusion The present study evaluating patterns of recurrence for WHO grade II meningiomas after surgical resection showed that recurrence occurred centrally and/or at the original tumor margin, with only a minority recurring > 1cm outside the original tumor margin.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome Induces Depression-Like Behavior and Learning-Memory Impairment: A Possible Link with Decreased Hippocampal Neurogenesis and Astrocyte Activation
Šutulović, Nikola , Vesković, Milena , Puškaš, Nela , Zubelić, Aleksa , Jerotić, Djurdja , Šuvakov, Sonja , Despotović, Sanja , Grubač, Željko , Mladenović, Dušan , Μacut, Djuro , Rašić-Marković, Aleksandra , Simić, Tatjana , Hrnčić, Dragan , Macut, Djuro , Stanojlović, Olivera , Hrnčić, Dragan , Simic, Tatjana

Mayo Clinic

Oxidative Medicine and Cellular Longevity | April 6, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-14

10.1155/2023/3199988 | PMID 37064799 Get It

Pathogenesis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains unclear since it represents an interplay between immunological, endocrine, and neuropsychiatric factors. Patients suffering from CP/CPPS often develop mental health-related disorders such as anxiety, depression, or cognitive impairment. The aim of this study was to investigate depression-like behavior, learning, and memory processes in a rat model of CP/CPPS and to determine the alterations in hippocampal structure and function. Adult male Wistar albino rats (n=6in each group) from CP/CPPS (single intraprostatic injection of 3% λ-carrageenan, day 0) and Sham (0.9% NaCl) groups were subjected to pain threshold test (days 2, 3, and 7), depression-like behavior, and learning-memory tests (both on day 7). Decreased pain threshold in the scrotal region and histopathological presence of necrosis and inflammatory infiltrate in prostatic tissue confirmed the development of CP/CPPS. The forced swimming test revealed the depression-like behavior evident through increased floating time, while the modified elevated plus maze test revealed learning and memory impairment through prolonged transfer latency in the CP/CPPS group in comparison with Sham (p<0.001andp<0.001, respectively). Biochemical analysis showed decreased serum levels of testosterone in CP/CPPS group vs. the Sham (p<0.001). The CP/CPPS induced a significant upregulation of ICAM-1 in rat cortex (p<0.05) and thalamus (p<0.01) and increased GFAP expression in the hippocampal astrocytes (p<0.01) vs. Sham, suggesting subsequent neuroinflammation and astrocytosis. Moreover, a significantly decreased number of DCX+ and Ki67+ neurons in the hippocampus was observed in the CP/CPPS group (p<0.05) vs. Sham, indicating decreased neurogenesis and neuronal proliferation. Taken together, our data indicates that CP/CPPS induces depression-like behavior and cognitive declines that are at least partly mediated by neuroinflammation and decreased neurogenesis accompanied by astrocyte activation.
Size-dependent differences in mitochondrial volume density in phrenic motor neurons
Fogarty, Matthew J. , Rana, Sabhya , Mantilla, Carlos B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B , Rana, S , Fogarty, Matthew J

Mayo Clinic

Journal of Applied Physiology | April 6, 2023 | Volume: 134 | Issue: 6 | Pages: 1332-1340

10.1152/japplphysiol.00021.2023 | PMID 37022966 Get It

Type S and FR motor units, comprising smaller phrenic motor neurons (PhMNs) are regularly activated to perform indefatigable ventilatory requirements. By contrast, type FF motor units, comprising larger PhMNs, are infrequently activated to perform expulsive straining and airway defense maneuvers. This difference in activation history is mirrored in the mitochondrial volume density (MVD), with smaller PhMNs having higher MVD than larger PhMNs. In proximal dendrites, this trend was reversed, with larger PhMNs having higher MVD than smaller PhMNs, likely due to the maintenance requirements for the larger dendritic arbor of FF PhMNs.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
Mesa, Ruben A. , Hudgens, Stacie , Floden, Lysbeth , Harrison, Claire , Palmer, Jeanne , Gupta, Vikas , McLornan, Donal P. , Kiladjian, Jean‐Jaques, Foltz, Lynda, Platzbecker, Uwe , Fox, María Laura , Mead, Adam J. , Perkins, Andrew C. , Leahy, Michael F. , Deheshi, Samineh, Donahue, Rafe, Klencke, Barbara , Verstovšek, Srđan , Verstovsek, Srdan , Platzbecker, Uwe , Mesa, Ruben , Mead, Adam J , McLornan, Donal , Gupta, Vikas , Perkins, Andrew C , McMullin, Mary Frances , Kiladjian, Jean‐Jacques , Ross, David M , Oh, Stephen T.

Mayo Clinic

Cancer Medicine | April 6, 2023 | Volume: 12 | Issue: 9 | Pages: 10612-10624

10.1002/cam4.5799 | PMID 37021939 Get It

AbstractBackgroundMyelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction ≥50% from baseline. However, this dichotomous assessment provides a limited view of clinically relevant symptomatic changes. Herein we evaluated longitudinal change from baseline in TSS over the continuous 24‐week period and individual symptom scores to obtain a more comprehensive understanding of symptom benefits experienced by patients with MF receiving therapy.MethodsLongitudinal symptom change was evaluated using mixed‐effect model repeated measure (MMRM) methodology with individual item‐level analyses to complement the interpretation of the landmark symptom results in the completed phase III SIMPLIFY studies of momelotinib in MF. MMRM compared mean change in TSS from baseline with Week 24 using data from all patient visits. Generalized estimating equations were used to estimate item‐level odds ratios using multiple predictive imputations for missing data.ResultsMomelotinib and ruxolitinib groups reported similar overall symptom improvements, with a TSS difference of <1.5 points between groups for each post‐baseline visit in SIMPLIFY‐1. In SIMPLIFY‐2, the improvement in TSS observed in momelotinib‐treated patients was consistent with that observed in SIMPLIFY‐1, whereas progressive TSS deterioration was observed with control. Item‐level scores were heterogeneous in both studies. A similar and greater proportion of momelotinib‐treated patients were categorized as “improved” or “stable” compared with control in SIMPLIFY‐1 and SIMPLIFY‐2, respectively. Odds ratios for between‐group comparison ranged from 0.75 to 1.21 in SIMPLIFY‐1, demonstrating similarity in likelihood of symptom improvement. In SIMPLIFY‐2, the likelihood of symptom improvement in each item was higher in the momelotinib arm.ConclusionsThese findings suggest that momelotinib provides clinically relevant symptom benefits in the JAK inhibitor‐naïve and JAK inhibitor‐exposed settings.
Comparison of complications for cirrhotic versus non-cirrhotic patients undergoing pancreaticoduodenectomy
Valencia, Paula Spang, Porrazzo, Gina, Almerey, Tariq , Zamorano, Alicia Amairan G. , Stauffer, John

Mayo Clinic

No container title available | April 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2777933/v1 Get It

Abstract Purpose To compare the outcomes between patients with cirrhosis and those without who have undergone pancreatoduodenectomy (PD) in our institution. Methods A review of patients undergoing PD from the time period of January 2010 to December 2020 was performed. Patients that have undergone open or laparoscopic PD and had liver cirrhosis diagnosed prior to surgery were included and matched on a 1:2 basis with non-cirrhotic patients based on age, gender, Eastern Cooperative Oncology Group (ECOG) and date of surgery. Data was obtained from our medical records and ten major postoperative complications variables were compared to the matched group. Results Overall, 16 patients with cirrhosis were compared to 32 matched controls. No significant differences were found in pancreatic fistula (18.8% vs. 21.8%; P = 1.000), hemorrhage (6.3% vs. 6.2%; P = 1.000), delayed gastric emptying (6.3% vs. 15.6%; P = 0.648), wound infection (0% vs. 9.3%; P = 0.541) intraabdominal abscess (31.2% vs 6.2%; 0.4998) for cirrhotic vs. non-cirrhotic respectively. There were no postop ileus, gastric fistula, mesenteric portal thrombosis, biliary fistula, abdominal ischemic event in either group. The average length of stay for both groups was similar (6.9 vs. 9.3 days; P = 0.4019). There were no mortalities and major morbidity was similar (37.5% vs 34.3%;P = 0.3549). One patient required readmission for liver-related decompensation with full recovery. Conclusion PD in patients with cirrhosis can be safe and feasible in well-selected patients. In a high-volume institution, postoperative complications are similar to those patients without cirrhosis of the liver
Endometrial safety of low-dose vaginal estrogens
Matharu, Harpreet, Stanczyk, Frank Z. , Mandelbaum, Rachel S. , Dancz, Christina Elizabeth , Sherman, Mark E.

Mayo Clinic

Menopause | April 6, 2023 | Volume: 30 | Issue: 6 | Pages: 650-658

10.1097/gme.0000000000002177 | PMID 37022294 Get It

Abstract It is estimated that up to 50% to 90% of postmenopausal women may experience genitourinary syndrome of menopause (GSM), which may have a detrimental impact on quality of life. One of the most effective modes of treatment of GSM is low-dose vaginal estrogens. Numerous studies have addressed the safety of these estrogens using endometrial biopsy and/or endometrial thickness on ultrasound. Based on these studies, the consensus is that low-dose vaginal estrogens do not substantially increase the risk of endometrial hyperplasia or cancer; however, the data are severely limited by short duration of follow-up. Although long-term trials are warranted, they are difficult to carry out, costly, and will not yield data for years. More immediate information regarding endometrial safety may be obtained from studies measuring endometrial tissue and serum concentrations of estradiol, estrone, and relevant equine estrogens after administration of different estrogen formulations and doses. This would allow us to understand better the metabolism of estrogens by the vagina and endometrium, and how much estrogen is reaching the endometrium. Here, we discuss metabolism, receptor binding, and signaling of estrogens in vaginal and endometrial tissue, and summarize the existing studies on the endometrial impact of low-dose vaginal estrogen treatment in postmenopausal women.